Oyster Point Pharma has announced that the Phase 3 ONSET-2 trial of the company's OC-01 varenicline nasal spray for the treatment of dry eye disease met its primary endpoint, demonstrating significant improvement in tear film production as measured by Schirmer's score for more patients using OC-01 than for patients using a control. A number of secondary endpoints were … [Read more...] about Phase 3 trial of Oyster Point’s OC-01 varenicline nasal spray for dry eye meets primary endpoint
Medical
iCAIR consortium initiates project to develop inhaled drugs for COVID-19
A consortium called Fraunhofer International Consortium for Anti-Infective Research (iCAIR) -- composed of researchers from Fraunhofer ITEM, Griffith University, Hannover Medical School, and Twincore -- has announced that it has initiated a project to develop inhaled drugs to treat COVID-19, starting with high-throughput screening for candidates by temporary … [Read more...] about iCAIR consortium initiates project to develop inhaled drugs for COVID-19
Pulmotect gets FDA okay for two Phase 2 trials of PUL-042 for the prevention and treatment of COVID-19
Pulmotect said that it plans to initiate two Phase 2 trials of its PUL-042 immunostimulant inhalation solution for the prevention and treatment of COVID-19 within a week after getting the go-ahead from the FDA. In January 2020, the company announced that preclinical studies of PUL-042, which is made up of Toll-like receptor agonists, demonstrated that it could protect … [Read more...] about Pulmotect gets FDA okay for two Phase 2 trials of PUL-042 for the prevention and treatment of COVID-19
FDA approves IND for Phase 2 study of GeneOne Life Science nasal spray for the prevention of COVID-19
The FDA has approved an IND for a Phase 2 study of GeneOne Life Science's GLS-1200 nasal spray for the prevention of COVID-19, the company said. According to GeneOne, GLS-1200 stimulates nasal production of nitric oxide, which has been shown to inhibit coronavirus activity. The study of GLS-1200 for prevention of COVID-19 is expected to enroll 225 healthcare … [Read more...] about FDA approves IND for Phase 2 study of GeneOne Life Science nasal spray for the prevention of COVID-19
AAAAI publishes new data showing bioequivalence of ARS Pharmaceuticals’ ARS-1 epinephrine nasal spray to injected epinephrine
The American Academy of Allergy, Asthma & Immunology (AAAAI) has published results of three Phase 1 studies of ARS Pharmaceuticals' ARS-1 (Neffy) intranasal epinephrine that had been scheduled for presentation at the AAAAI annual meeting. The FDA granted Fast Track designation to the ARS-1 for the treatment of anaphylaxis in February 2019. The studies, EPI … [Read more...] about AAAAI publishes new data showing bioequivalence of ARS Pharmaceuticals’ ARS-1 epinephrine nasal spray to injected epinephrine
Alnylam and Vir select candidate for development as inhaled COVID-19 vaccine
Alnylam Pharmaceuticals and Vir Biotechnology have announced that they intend to meet with the FDA soon regarding an IND for VIR-2703 (ALN-COV), an inhaled siRNA in development for prevention and/or treatment of COVID-19. The companies said that VIR-2703 may also have activity against other coronaviruses. The collaboration agreement between Vir and Alnylam includes … [Read more...] about Alnylam and Vir select candidate for development as inhaled COVID-19 vaccine
Fluidda study suggests that inhaled vasodilators may be helpful in COVID-19
Functional respiratory imaging (FRI) company Fluidda has announced that an FRI study of COVID-19 patients has shown that the virus is resulting in narrowing of small capillaries in the lung, resulting in higher flow pressures that in turn causes higher pressure in the main blood vessels and suggests that vasodilators delivered to the lung may be a useful therapy. … [Read more...] about Fluidda study suggests that inhaled vasodilators may be helpful in COVID-19
Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia
Marinomed Biotech has announced new funding from the Austrian Research Promotion Agency (FFG) for development of a Carragelose inhalation solution for COVID-19 pneumonia. The funding is part of the FFG's "Emergency Call to research COVID-19 in the wake of the outbreak of SARS-CoV-2." Carragelose is a polymer derived from red seaweed that has shown activity against … [Read more...] about Marinomed gets funding for development of Carragelose inhalation solution for the treatment of COVID-19 pneumonia
Alpha Cognition and Linical partner on potential intranasal therapy for Alzheimer’s disease
Alpha Cognition Inc. (formerly Neurodyn Cognition) and CRO Linical have announced Linical will provide consulting services related to potential development of Alpha Cognition's Alpha-1062 acetyl choline esterase inhibitor (AChEI) for the treatment of Alzheimer's disease. Linical's services are expected to encompass a range of areas, including regulatory guidance, … [Read more...] about Alpha Cognition and Linical partner on potential intranasal therapy for Alzheimer’s disease
Phase 2a trial of Biomarck’s inhaled peptide for acute respiratory distress syndrome meets its primary endpoint
Biomarck Pharmaceuticals said that a Phase 2a clinical trial of its BIO-11006 inhalation solution in patients with acute respiratory distress syndrome (ARDS) met its primary endpoint, with a 43% decrease in mortality at 28 days compared to placebo. According to Biomarck, previous studies have shown that BIO-11006, the 10 amino acid N-terminal of a protein called … [Read more...] about Phase 2a trial of Biomarck’s inhaled peptide for acute respiratory distress syndrome meets its primary endpoint